SCHEMBL3480315

SCHEMBL3480315

c1cc2cc(CN3CCOCC3)ccc2s1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 1/20 0.54
HRH3 Q9Y5N1 2/20 0.51
CYP2A6 P11509 1/20 0.50
NCF1 P14598 1/20 0.48
HTT P42858 3/20 0.47
MCHR1 Q99705 2/20 0.46
SMN1; SMN2 Q16637 5/20 0.46
NPC1 O15118 2/20 0.46
TP53 P04637 2/20 0.46
RAB9A P51151 2/20 0.46
TSHR P16473 1/20 0.46
MAPK1 P28482 1/20 0.46
KDM1A O60341 1/20 0.45
RCOR1 Q9UKL0 1/20 0.45
ALDH1A1 P00352 2/20 0.43
KDM4E B2RXH2 1/20 0.43
HPGD P15428 1/20 0.43
KCNH2 Q12809 1/20 0.43
MCHR2 Q969V1 1/20 0.43
LMNA P02545 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13293667 0.84 SMN1; SMN2 (0.54) HRH3CYP2A6HTTMCHR1SMN1; SMN2
SCHEMBL11517673 0.82 CYP2A6 (0.50) HRH3CYP2A6MCHR1
SCHEMBL20021994 0.74 KMT2A (0.70) HRH3NCF1HTTSMN1; SMN2NPC1
SCHEMBL15467001 0.74 HRH3 (0.87) HRH3NCF1SMN1; SMN2ALDH1A1HPGD
SCHEMBL5618352 0.74 SMN1; SMN2 (0.71) HRH3NCF1SMN1; SMN2NPC1TP53
SCHEMBL2984739 0.73 ALDH1A1 (0.61) CA2HRH3NPC1TP53RAB9A
SCHEMBL10369679 0.73 SLC6A2 (0.57) HTTSMN1; SMN2NPC1TP53RAB9A
SCHEMBL22470723 0.72 HRH3 (0.54) CA2HRH3NCF1HTTSMN1; SMN2
SCHEMBL12123860 0.72 ALDH1A1 (0.62) HTTSMN1; SMN2NPC1TP53RAB9A
SCHEMBL3480061 0.72 CA2 (0.98) CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2049200-B1 NOVEL INHIBITORS OF BETA-LACTAMASE METHYLGENE INC (CA) 2015-04-29 EP disclosed
US-8440643-B2 Inhibitors of beta-lactamase METHYLGENE INC. (CA) 2013-05-14 US disclosed
US-20100317625-A1 NOVEL SULFONAMIDOMETHYLPHOSPHONATE INHIBITORS OF BETA-LACTAMASE 92229129 QUEBEC INC. (CA) 2010-12-16 US disclosed
US-20100279983-A1 NOVEL INHIBITORS OF BETA-LACTAMASE METHYLGENE INC. 2010-11-04 US disclosed
EP-2049200-A2 NOVEL INHIBITORS OF BETA-LACTAMASE MethylGene Inc. (CA) 2009-04-22 EP disclosed
EP-2024376-A1 NOVEL SULFONAMIDOMETHYLPHOSPHONATE INHIBITORS OF BETA-LACTAMASE Merck & Co., Inc. (US) 2009-02-18 EP disclosed
WO-2008073142-A2 NOVEL INHIBITORS OF BETA-LACTAMASE MERCK & CO., INC. (US) 2008-06-19 WO disclosed
WO-2007139729-A1 NOVEL SULFONAMIDOMETHYLPHOSPHONATE INHIBITORS OF BETA-LACTAMASE MERCK & CO., INC. (US) 2007-12-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317625-A1 NOVEL SULFONAMIDOMETHYLPHOSPHONATE INHIBITORS OF BETA-LACTAMASE MGAM, BPGM, PPME1 CA2 2070/4885HRH3 3961/4885CYP2A6 745/4885
US-20100279983-A1 NOVEL INHIBITORS OF BETA-LACTAMASE MGAM, MGAM2, PGLS CA2 440/4885HRH3 2447/4885CYP2A6 944/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.